<DOC>
	<DOCNO>NCT01560143</DOCNO>
	<brief_summary>If tigecycline clearance increase body size serum exposure value low obese class III compare normal weight subject exposure change inversely clearance dose fix without regard weight .</brief_summary>
	<brief_title>Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects</brief_title>
	<detailed_description>Not require</detailed_description>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Subjects fulfil follow criterion eligible : 1. male female , 18 50 year age ; 2. nonsmoking lightsmoking ( ≤ 5 cigarette per day ) volunteer ; 3 . Body mass index : 18.5024.99 kg/m2 ( normal weight ) ≥ 40 kg/m2 ( obese class III ) ; 4. female subject childbearing potential ( selfreported ) either surgically sterilize , use effective method contraception ( diaphragm , cervical cap , condom ) agree abstain sex time prestudy screening , entire study period 1 month follow study period 1. history significant hypersensitivity reaction component Tygacil® ; 2. history significant clinical illness require pharmacological management ; 3. history blood donation past eight week period ; 4. abnormal serum electrolyte complete blood count require clinical workup ; 5. transaminase ( AST ALT ) &gt; 2.5 x upper limit normal ; 6. subject stage 4 5 chronic kidney disease ; 7. positive serum pregnancy test ( female ) ; 8. abnormal electrocardiogram ( ECG ) judge study physician ; 9. unable tolerate venipuncture multiple blood draw ; 10. clinically significant abnormal physical examination define physical finding require clinical workup ; 11. unable independently provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>